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ABSTRACT: Proton pump inhibitor has been reported to cause myopathic adverse drug reactions in sev-
eral overseas countries. Unfortunately, this case has never been raised and has not received much attention 
in Indonesia. A case about myopathy associated with lansoprazole in 48-years old man has been recently re-
ported in Indonesia. Assessment methods used were time series data collection followed by causality analy-
sis using Naranjo Scale. The results of analysis revealed a Naranjo Scale of 9, which was interpreted as defi-
nite. This report concluded that lansoprazole could triggered myopathy adverse drug reaction in some sen-
sitive patient. The mechanism presumably through inhibition of H+K+-ATPase in other tissue which can lead 
destruction of myofibril and leakage of calcium, pottasium, phosphate, myoglobin, creatine phosphokinase, 
lactate dehydrogenase, and aspartate transaminases from the muscle. This case report aims to remind 
health professionals to pay more attention at possible myopathy adverse drug reactions in the use of lanso-
prazole and other proton pump inhibitors, so that more serious adverse drug reactions could be prevented.
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1. Introduction 
Proton pump inhibitors (PPI) are the first line recommendation to relieve severe gastrointesti-
nal problem caused by over-secretion of gastric 
acid. PPI are a class of medication which inhibit 
the H+K+-ATPase in parietal cells to suppress gas-
tric acid secretion [1,2]. As of 2015, there are five 
PPI that are approved both by United Stated and 
Indonesian Food and Drug Administration (FDA) including omeprazole, lansoprazole, esomepra-
zole, rabeprazole, and pantoprazole [3,4]. 
PPI become the first line recommendation of acid-related disorder because it is considered as 
effective and safe [2,4,5].  Since its FDA approval, several case report from overseas countries that 
reported myopathy adverse drug reaction in pa-
tients who received PPI have been slowly emer-
ging [5,8]. Myopathy is a term used to define any disease of the muscle that presented as muscle 
cramps, myalgia, joint pain, leg pain, back pain, or 
muscle weakness [1,5]. 
An evaluation of myopathy conducted by Ca-
pogrosso-Sansone et all. (2014) using the data 
obtained from 255,548 patients who received 
PPI since January 1988 until July 2014 report-
ed adjusted odd ratio (aOR) (95% CI) of 1.237 
(1.101-1.389), p<0.001 [9]. Lansoprazole as one 
type of the PPI was reported to have higher my-
opathy and rhabdomyolysis aOR compared to 
omeprazole. Lansoprazole demonstrated aOR 
(CI 95%) of 2.687, 95%CI:1.778-4.062, p<0.001 while omeprazole demonstrated aOR (CI 95%) of 
(aROR:1.996, 95%CI:2.027-4.428, p<0.001) [9]. 
SIDER data base of lansoprazole (http://sideef-
fects.embl.de/drugs/3883/) demonstrated that 
myopathy or myositis side effect has been repor-
ted on post marketing surveillance, but there has 
been no report on the frequency of the incidence.
(10,11) 
Neither PPI induced myopathy nor lansopra-
zole induced myopathy case has been reported in 
Indonesia. In this article, we review a case report 
of myopathy adverse drug reaction associated 
with lansoprazole in an Indonesian patient. This case report aims to remind health professionals 
in Indonesia to pay more attention at possible 
myopathy adverse drug reactions in the use of 
lansoprazole and other proton pump inhibitors. Therefore, more serious adverse drug reactions 
could be prevented.
2. Case Presentation
Mr. LD a 48-year-old male patient, 70 kg, 165 cm, was complaining heartburn, epigastric pain, 
and dyspepsia on June 20th, 2017. He was visiting his doctor in outpatient clinic at a private hospi-
tal in Surabaya and was diagnosed as gastritis. He 
Figure 1. Myopathy time series of the patient. Myopathy was developed three days after starting lan-
soprazole for the first time and later on when it is restarted. Myopathy was recovered after 
lansoprazole was discontinued on both occasion.
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was prescribed 30 mg fast dissolved lansopra-
zole once daily. Patient has neither medical his-
tory nor medication history. On June 23rd, 2017 patient started complaining muscle cramp and 
shoulder pain (myopathy) especially at night.  On 
June 30th, 2017 patient was still complaining the 
same condition and went back to the outpatient 
pharmacy to report his condition (pain scale: 8 
out of 10). The outpatient pharmacist asked for 
other possible condition such as injury or statin 
consumption history but found nothing has been 
the particular cause of the complains. The phar-macist has consulted the doctor and suggested 
the patient to stop the lansoprazole. On July 1st, 
2017 the patient stopped taking lansoprazole. On 
July 2nd – July 3rd, 2017, after the medication was stopped the patient still felt the pain but the in-
tensity decreases (pain scale: 3 out of 10). On July 
4th, 2017 the muscle cramp and shoulder pain 
(myopathy) were completely gone. Pharmacist 
asked patient to retake the medication and it re-
sulted with the same complain (pain scale: 7 out 
of 10). The pain was relieved when the medica-
tion has been stopped for two days (pain scale: 0 
out of 10). 
3. Results and discussion
Myopathy is defined as the acute or subacute 
manifestation of muscle weakness, myalgia, and 
sometimes presented in the laboratory data as 
elevated creatine phosphokinase level or myo-
globinuria. There are several causes of myopa-
thy such as family history of periodic paralysis 
or muscle dystrophy, personal medical history 
of autoimmune disease, endocrinopathy, renal 
insufficiency, alcoholism, previous episodes of 
sever weakness, muscle injury, occupational or 
travel history that caused potential ingestion of barium chloride or carbonate, and medication 
history such as lipid lowering agents, antiretrovi-
ral, and colchicine [12,13]. The patient had none 
of this condition, except a history of gastritis and 
lansoprazole.  
Lansoprazole is included in PPI class therapy. PPI are an important class of medication for the management of over secretion of gastric acid, 
GERD, Barret’s esophagus, peptic ulcer and gas-
trointestinal bleeding [14]. Generally, PPI are 
very safe medication, but a few case reports have 
implicated that their used may associated with 
myopathy adverse drug reaction [1,5].  A review 
of 12 case reports conducted by Colmenares et 
all. (2017) has demonstrated that patients devel-
oping myopathy after PPI administration. One of the reported case was also happened after the ad-
ministration of lansoprazole.  
In this 48-year-old patient case, a Naranjo 
Scale analysis was performed. The results of ana-
Figure 2. Time series of patient myopathy pain scale 
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Table 1. Naranjo Scale
No Question Yes No Do Not 
Know
Score
1 Are there previous conclusive report on this re-action +1 0 0 1
2 Did the adverse event appear after the suspected drug was administered? +2 -1 0 2
3 Did the adverse event improve when the drug 
was discontinued or a specific antagonist was administered?
+1 0 0 1
4 Did the adverse event reappear when the drug was readministered? +2 -1 0 2
5 Are there alternative causes that could on their own have caused the reaction? -1 +2 0 2
6 Did the reaction reappear when a placebo was given? -1 +1 0 0
7 Was the drug detected in blood or other fluids in 
concentrations known to be toxic?
+1 0 0 0
8 Was the reaction more severe when the dose was increased or less severe when the dose was decreased?
+1 0 0 0
9 Did the patient have a similar reaction to the 
same or similar drugs in any previous exposure?
+1 0 0 0
10 Was the adverse event confirmed by any objec-tive evidence? +1 0 0 1
Total Naranjo Score 9
Table 2. Naranjo Algorithm - ADR Probability Scale Naranjo
Score Question
Total Score ≥9 Definite. The reaction (1) followed a reasonable temporal sequence after a drug 
or in which a toxic drug level had been established in body fluids or tissues, (2) 
followed a recognized response to the suspected drug, and (3) was confirmed by 
improvement on withdrawing the drug and reappeared on re-exposure.
Total Score 5 to 8 Probable. The reaction (1) followed a reasonable temporal sequence after a drug, 
(2) followed a recognized response to the suspected drug, (3) was confirmed by 
withdrawal but not byexposure to the drug, and (4) could not be reasonably ex-
plained by the known characteristics of the patient’s clinical state.
Total Score 1 to 4 Possible. The reaction (1) followed a temporal sequence after a drug, (2) possibly 
followed a recognized pattern to the suspected drug, and (3) could be explained by 
characteristics of the patient’s disease.
Total Score ≤0 Doubtful. The reaction was likely related to factors other than a drug.
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lysis revealed a Naranjo Scale of 9, which was in-
terpreted as definite. It is shown a high certainty, 
that lansoprazole is suspected as a trigger of my-
opathy. The following are the results of the Nara-
njo scale analysis (Table 1 and Table 2).
The potential mechanism of myopathy associ-
ated with lansoprazole has not yet been elucida-
ted. Lansoprazole is known to bind specifically to 
H+K+-ATPase at the parietal cell on the stomach. 
H+K+-ATPase is present not only in parietal cells 
but also in other tissue including the muscle cells. 
Blocking H+K+-ATPase may induce destruction 
of myofibril and leakage of calcium, potassium, 
phosphate, myoglobin, creatine phosphokinase, 
lactate dehydrogenase, and aspartate transami-
nases from the muscle.
Myopathy time to onset was occurred with the 
first week of PPI in 9 cases reported by Clark and 
Strandel (2006) and in 2 cases reported by Dun-
can and Howards (2017). The reaction occurred 
between 14 days to 4 months of PPI treatment 
in 3 cases was reported by Clark and Strandel 
while 3 cases was reported on Duncan and How-
den (2017) [1,15]. Where in Mr. LD cases the first 
three days after Lansoprazole was first adminis-
tered.
Interestingly Clark and Strandel (2006) the 
myopathy syndroms even more severe in 57% of 
cases where concomitant medication was used. 
The co-reported medications were statin taken 
concomitantly (34 case reports), clarithromycin 
(11 case reports), aspirin (15 case reports), and 
ranitidine (13 case reports). Which none of the 
medication was noted in Mr. LD case.  
In total of 292 cases reported by Clark and 
Strandel (2006) the analysis result demonstra-
ted that 69 patients recovered when the drug 
was stopped and in 15 patients, the reaction re-
occurred when the drug was re-challenged [1]. 
This profile was similar compared to the profile 
of Mr. LD in this article. Mr. LD myopathy symp-
toms was fully terminated when lansoprazole 
was stopped for three days, and the symptoms of 
myopathy was positive when lansoprazole was 
re-challanged.
The profile single administered lansoprazole 
induced myopathy in Mr. LD case was also simi-
lar with several cases reported both in Clark and 
Strandel (2006) and Duncan and Howden (2017). 
In 33% of the 292 cases reported by Clark and 
Strandel (2006) the PPI was a single adminis-
tered drug. In 3 cases reported by Duncan and 
Howden (2017) the PPI was also a single admin-
istered drug [1,15]. 
Myopathy associated with lansoprazole did 
not typically result in long-term effects. The symp-
toms were gone less than a week post-disconti-
nuation of lansoprazole. Although the prevalence 
is rare, physician, pharmacist and other health care professional should put their consideration 
on it. Lack of consideration and late detection of 
the symptoms might lead to more severe side ef-
fect such as rhabdomyolysis as reported on Dun-
can and Howden (2017) and Tanaka et all. (2014)
[15,16]. 
4. Conclusions
A causal association of myopathy with lanso-
prazole is consistent with literature review. This case report supported a causal association with 
Naranjo Scale of 9, which is described as defi-
nite. Myopathy associated with lansoprazole did 
not typically result in long-term effects after the 
me dication was stopped. Although myopathy is a rare adverse drug reaction in lansoprazole or o ther PPI, it can be a serious side effect that should be considered when dispense acid sup-
pression medication to patients.
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